Leerink Partners Initiates Coverage On Whitehawk Therapeutics with Outperform Rating, Announces Price Target of $9

Benzinga Newsdesk www.benzinga.com Positive 75.5%

Neg 0% Neu 0% Pos 75.5%

Leerink Partners analyst Jonathan Chang initiates coverage on Whitehawk Therapeutics (NASDAQ:WHWK) with a Outperform rating and announces Price Target of $9.